Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 NEC Corporation Nov 08, 2024 09:31 HKT/SGT Read More
NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting NEC Corporation Nov 07, 2024 10:40 HKT/SGT Read More
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" Eisai Nov 05, 2024 10:35 HKT/SGT Read More
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status Eisai Nov 01, 2024 12:56 HKT/SGT Read More
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference Eisai Oct 31, 2024 12:56 HKT/SGT Read More
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) Eisai Oct 31, 2024 10:33 HKT/SGT Read More
Machine learning can predict the mechanical properties of polymers Science and Technology of Advanced Materials Oct 26, 2024 23:08 JST Read More
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' Hua Medicine Oct 25, 2024 09:18 HKT/SGT Read More
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 HighTide Therapeutics Inc. Oct 25, 2024 08:57 HKT/SGT Read More
T.MAN Pharmaceutical PCL (SET: TMAN) Showcases Leadership in Health Innovation, Aiming for Sustainable Growth Following Listing on SET T.MAN Pharmaceutical PCL Oct 23, 2024 09:00 HKT/SGT Read More
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study Lexaria Bioscience Oct 22, 2024 21:20 HKT/SGT Read More
Acrometa Group to Divest Its Life Sciences Business, Pursue New Business Opportunities in the Region AcroMeta Group Limited Oct 21, 2024 22:50 HKT/SGT Read More
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association Eisai Oct 17, 2024 19:01 HKT/SGT Read More
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia Eisai Oct 17, 2024 14:59 HKT/SGT Read More
Athos宣佈其人工智慧生成的全新口服G9A抑製劑ATH-063的I期臨床試驗頂線數據,顯示其對強效抗炎調節性T細胞的選擇性擴增和啟動 Athos Therapeutics, Inc Oct 17, 2024 08:00 HKT/SGT Read More
Athos宣布其人工智能生成的全新口服G9A抑制剂ATH-063的I期临床试验顶线数据,显示其对强效抗炎调节性T细胞的选择性扩增和激活 Athos Therapeutics, Inc Oct 17, 2024 08:00 HKT/SGT Read More
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells Athos Therapeutics, Inc Oct 17, 2024 08:00 HKT/SGT Read More